Clinical Trial 21921

A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma

Disease Site: Breast, Liver, Other Digestive Organ, Other Female Genital, Ovary

PI: Soliman, Hatem

Clinical Trial 21046

Phase I Trial with Expansion Cohort of Obp-301 (Telomelysintm) And Definitive Chemoradiation For Patients with Locally Advanced Esophageal And Gastroesophageal Adenocarcinoma Who Are Not Candidates For Surgery

Disease Site: Esophagus

PI: Mehta, Rutika

Clinical Trial 20530

Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Alectinib, Entrectinib, or Vemurafenib Plus Cobimetinib in Patients with Stages I-III Non-Small Cell Lung Cancer with ALK, ROS1, NTRK, or BRAF V600E Molecular Alterations

Disease Site: Lung

PI: Saltos, Andreas

Clinical Trial 20752

A Phase 1 Study of Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated Acute Myeloid Leukemia

Disease Site: Leukemia, other, Myeloid and Monocytic Leukemia

PI: Chan, Onyee

Clinical Trial 22595

Disease Site: Multiple Myeloma

PI: Paba Prada, Claudia

Clinical Trial 20178

An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC

Disease Site: Lung, Non small cell lung cancer

PI: Saltos, Andreas

Clinical Trial 20110

GBM Agile: Global Adaptive Trial Master Protocol

Disease Site: Brain and Nervous System

PI: Grogan, Patrick

Clinical Trial 21887

A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes

Disease Site: Leukemia, other

PI: Padron, Eric

Clinical Trial 21997

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

Disease Site: Other Skin

PI: Eroglu, Zeynep

Clinical Trial 22002

A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS

Disease Site: Any Site, Liver, Lung, Other Digestive Organ, Pancreas, Small Intestine, Stomach

PI: Kim, Dae Won

Clinical Trial 22003

A Phase II Randomized Study of Sipuleucel-T with or without Continuing New Hormonal Agents (NHA) in Metastatic Prostate Cancer with PSA Progression while on NHA and LHRH Analog

Disease Site: Prostate

PI: Zhang, Jingsong

Clinical Trial 22254

A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination with Pembrolizumab in Subjects with Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2

Disease Site: Urinary Bladder

PI: Jain, Rohit